Ask AI
ProCE Banner Activity

Redefining the Therapeutic Paradigm in B-Cell ALL: From Incremental Gains to Transformative Immunotherapy

Clinical Thought

Learn how continuing innovations with immunotherapies are impacting the therapeutic paradigm for patients with B-cell ALL in this expert-authored commentary.

Released: May 06, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This educational activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with ALL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply increased knowledge of clinical and molecular features that influence the selection and sequencing of immune-targeted therapies in acute lymphoblastic leukemia (ALL)

  • Integrate emerging evidence from clinical trials, recent approvals, and updated guideline recommendations for bispecific T-cell engagers and CAR T-cell therapies into the management of patients with ALL

  • Develop evidence-based strategies to proactively recognize and manage adverse events associated with immune-targeted agents, supporting early intervention and sustained patient benefit in ALL care

Disclosure

Primary Author

Ibrahim Aldoss, MD, has no relevant financial relationships to disclose.